Joseph Mathew
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joseph Mathew has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Avanish Saklani
Division of Colo‐Rectal and Peritoneal Surface Oncology, Department of Surgical Oncology Tata Memorial Hospital, Homi Bhabha National Institute Mumbai India
6 shared publications - Mufaddal Kazi
Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
5 shared publications Ashwathappa Dasappa
Department of Surgical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India
3 shared publications- Ashwin Desouza
Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
3 shared publications Ravi Arjunan
Department of Surgical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India
3 shared publications- ArunKumar Namachivayam
Department of Biostatistics, Bapuji Dental College and Hospital, Davangere, India
2 shared publications
Latest Publications
- Open Access
- 7 March 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (3) , e70174
Laparoscopic Versus Robotic Lateral Pelvic Lymph Node Dissection in Locally‐Advanced Rectal Cancer: A Cohort Study Comparing Perioperative Morbidity and Short‐Term Oncological Outcomes
Background: Robotic surgery has been associated with superior short‐term outcomes in patients undergoing total mesorectal excision (TME) for organ‐confined rectal cancer. However, whether this approach offers an additional benefit over laparoscopy when performing lateral pelvic lymph node dissection (LPLND) with TME or extended TME (e‐TME) in locally advanced rectal cancer (LARC) is not known.Aims: This study was conducted to evaluate the outcomes of robotic and laparoscopic LPLND in patients with lateral pelvic node‐positive LARC with reference to intraoperative safety, postoperative morbidity, pathological indices including nodal yield and node positivity rates, lateral pelvic recurrence rates, and short term event‐free and overall survival.Methods and Results: In this retrospective single‐center study, consecutive patients with non‐metastatic histologically proven LARC and clinically significant lateral pelvic lymphadenopathy who had undergone laparoscopic or robotic LPLND with TME or e‐TME between 2014 and 2023 were included, all procedures having been performed by minimal‐access colorectal surgeons who were beyond the learning curve for either surgical approach. Of the 115 patients evaluated, 98.3% received neoadjuvant chemoradiotherapy, following which 27 (23.5%) underwent robotic and 88 (76.5%) laparoscopic LPLND with TME or e‐TME. The baseline clinicodemographic features, treatment‐related characteristics, and proportion of patients undergoing extended resections for persistent circumferential resection margin‐positive rectal cancer (22.7% vs. 18.5%, respectively) were statistically similar in both groups. When comparing robotic with laparoscopic resections, no significant difference was observed in intraoperative parameters including procedure‐associated blood loss (median 250 mL vs. 400 mL) and on‐table adverse events or conversion rates (none in either group), postoperative outcomes comprising clinically significant early (14.8% vs. 9.1%), intermediate (5.3% vs. 1.9%) and late (5.3% vs. 2.0%) surgical morbidity, re‐exploration rates (7.4% vs. 3.4%) and duration of hospital stay (median 6 days in both groups), or the pathological quality indices of margin involvement (7.4% vs. 2.3%), nodal yield (median 4 vs. 7 nodes) and lateral node positivity (22.2% vs. 26.1%), respectively. At a median 11 months follow‐up, oncological outcomes in terms of lateral pelvic recurrence rates (3.7% vs. 4.5%), 2‐year event‐free survival (78.7% vs. 79.3%) and 2‐year overall survival (83.1% vs. 93.8%) were also comparable.Conclusion: Surgical competence in laparoscopy may offset the potential benefits extended by robotic platforms. In a high‐volume setup with experienced minimal‐access surgeons, the clinical, pathological, and short‐term oncological outcomes associated with both approaches may be considered equivalent.
- 7 March 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (3) , e70174
Open AccessLaparoscopic Versus Robotic Lateral Pelvic Lymph Node Dissection in Locally‐Advanced Rectal Cancer: A Cohort Study Comparing Perioperative Morbidity and Short‐Term Oncological Outcomes
Background: Robotic surgery has been associated with superior short‐term outcomes in patients undergoing total mesorectal excision (TME) for organ‐confined rectal cancer. However, whether this approach offers an additional benefit over laparoscopy when performing lateral pelvic lymph node dissection (LPLND) with TME or extended TME (e‐TME) in locally advanced rectal cancer (LARC) is not known.Aims: This study was conducted to evaluate the outcomes of robotic and laparoscopic LPLND in patients with lateral pelvic node‐positive LARC with reference to intraoperative safety, postoperative morbidity, pathological indices including nodal yield and node positivity rates, lateral pelvic recurrence rates, and short term event‐free and overall survival.Methods and Results: In this retrospective single‐center study, consecutive patients with non‐metastatic histologically proven LARC and clinically significant lateral pelvic lymphadenopathy who had undergone laparoscopic or robotic LPLND with TME or e‐TME between 2014 and 2023 were included, all procedures having been performed by minimal‐access colorectal surgeons who were beyond the learning curve for either surgical approach. Of the 115 patients evaluated, 98.3% received neoadjuvant chemoradiotherapy, following which 27 (23.5%) underwent robotic and 88 (76.5%) laparoscopic LPLND with TME or e‐TME. The baseline clinicodemographic features, treatment‐related characteristics, and proportion of patients undergoing extended resections for persistent circumferential resection margin‐positive rectal cancer (22.7% vs. 18.5%, respectively) were statistically similar in both groups. When comparing robotic with laparoscopic resections, no significant difference was observed in intraoperative parameters including procedure‐associated blood loss (median 250 mL vs. 400 mL) and on‐table adverse events or conversion rates (none in either group), postoperative outcomes comprising clinically significant early (14.8% vs. 9.1%), intermediate (5.3% vs. 1.9%) and late (5.3% vs. 2.0%) surgical morbidity, re‐exploration rates (7.4% vs. 3.4%) and duration of hospital stay (median 6 days in both groups), or the pathological quality indices of margin involvement (7.4% vs. 2.3%), nodal yield (median 4 vs. 7 nodes) and lateral node positivity (22.2% vs. 26.1%), respectively. At a median 11 months follow‐up, oncological outcomes in terms of lateral pelvic recurrence rates (3.7% vs. 4.5%), 2‐year event‐free survival (78.7% vs. 79.3%) and 2‐year overall survival (83.1% vs. 93.8%) were also comparable.Conclusion: Surgical competence in laparoscopy may offset the potential benefits extended by robotic platforms. In a high‐volume setup with experienced minimal‐access surgeons, the clinical, pathological, and short‐term oncological outcomes associated with both approaches may be considered equivalent.
- Open Access
- 1 January 2025
- Published by KEAI Publishing in Intelligent Surgery
- Vol. 8, 67-69
Utility of the da Vinci X robotic system in extramesocolic resections for locally-advanced colon cancer: A video vignette
- 1 January 2025
- Published by KEAI Publishing in Intelligent Surgery
- Vol. 8, 67-69
Open AccessUtility of the da Vinci X robotic system in extramesocolic resections for locally-advanced colon cancer: A video vignette
- Open Access
- 24 October 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (1) , 165-175
Postoperative Morbidity and Factors Predicting the Development of Lymphoceles Following Lateral Pelvic Node Dissection for Rectal Cancer: A Cohort Study
Purpose: Lateral pelvic node dissection (LPLND) is indicated in the surgical management of clinically significant pelvic lymphadenopathy associated with rectal malignancies. However, procedure-related morbidity, including the incidence and predisposing factors for lymphoceles arising in this setting have not been adequately evaluated. Methods: This retrospective single-institution study included 183 patients with nonmetastatic, lateral node-positive rectal cancer undergoing total mesorectal excision with LPLND between June 2014 and May 2023 to determine the incidence and severity of postoperative complications using the Clavien-Dindo system, with logistic regression performed to model a relationship between lymphocele-development and potentially-predictive variables. Results: In this cohort, mean age was 45.3 ± 12.81 years, 62.8% were male, and 27.9% had body mass index ≥ 25 kg/m2. Median tumor-distance from the verge was 3.0 (interquartile range [IQR] 1.0–5.0) cm. Following radiotherapy in 86.9%, all patients underwent surgery: 30.1% had open resection and 26.2% had bilateral LPLND. Median nodal-yield was 6 (IQR 4–8) per side. Postoperatively, 45.3% developed complications, with 18% considered clinically significant. Lymphoceles, detected in 21.3%, comprised the single-most common sequelae following LPLND, 46.2% arising within 30 days of surgery and 33.3% requiring intervention. On multivariate analyses, obesity (hazard ratio [HR] 2.496; 95% confidence interval [CI] 1.094–5.695), receipt of preoperative radiation (HR 10.026; 95% CI 1.225–82.027), open surgical approach (HR 2.779; 95% CI 1.202–6.425), and number of harvested nodes (HR 1.105; 95% CI 1.026–1.190) were significantly associated with lymphocele-development. Conclusions: Pelvic lymphoceles and its attendant complications represent the most commonly encountered morbidity following LPLND for rectal cancer, with obesity, neoadjuvant radiotherapy, open surgery, and higher nodal-yield predisposing to their development.
- 24 October 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (1) , 165-175
Open AccessPostoperative Morbidity and Factors Predicting the Development of Lymphoceles Following Lateral Pelvic Node Dissection for Rectal Cancer: A Cohort Study
Purpose: Lateral pelvic node dissection (LPLND) is indicated in the surgical management of clinically significant pelvic lymphadenopathy associated with rectal malignancies. However, procedure-related morbidity, including the incidence and predisposing factors for lymphoceles arising in this setting have not been adequately evaluated. Methods: This retrospective single-institution study included 183 patients with nonmetastatic, lateral node-positive rectal cancer undergoing total mesorectal excision with LPLND between June 2014 and May 2023 to determine the incidence and severity of postoperative complications using the Clavien-Dindo system, with logistic regression performed to model a relationship between lymphocele-development and potentially-predictive variables. Results: In this cohort, mean age was 45.3 ± 12.81 years, 62.8% were male, and 27.9% had body mass index ≥ 25 kg/m2. Median tumor-distance from the verge was 3.0 (interquartile range [IQR] 1.0–5.0) cm. Following radiotherapy in 86.9%, all patients underwent surgery: 30.1% had open resection and 26.2% had bilateral LPLND. Median nodal-yield was 6 (IQR 4–8) per side. Postoperatively, 45.3% developed complications, with 18% considered clinically significant. Lymphoceles, detected in 21.3%, comprised the single-most common sequelae following LPLND, 46.2% arising within 30 days of surgery and 33.3% requiring intervention. On multivariate analyses, obesity (hazard ratio [HR] 2.496; 95% confidence interval [CI] 1.094–5.695), receipt of preoperative radiation (HR 10.026; 95% CI 1.225–82.027), open surgical approach (HR 2.779; 95% CI 1.202–6.425), and number of harvested nodes (HR 1.105; 95% CI 1.026–1.190) were significantly associated with lymphocele-development. Conclusions: Pelvic lymphoceles and its attendant complications represent the most commonly encountered morbidity following LPLND for rectal cancer, with obesity, neoadjuvant radiotherapy, open surgery, and higher nodal-yield predisposing to their development.
- Open Access
- 24 October 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (1) , 188
ASO Visual Abstract: Postoperative Morbidity and Factors Predicting the Development of Lymphoceles following Lateral Pelvic Node Dissection for Rectal Cancer—A Cohort Study
- 24 October 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (1) , 188
Open AccessASO Visual Abstract: Postoperative Morbidity and Factors Predicting the Development of Lymphoceles following Lateral Pelvic Node Dissection for Rectal Cancer—A Cohort Study
- 28 May 2024
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 15 (4) , 661-670
Single-Tracer Methylene Blue-Guided Sentinel Lymph Node Biopsy in Early-Stage Squamous Cell Carcinoma of the Buccal Mucosa: A Prospective Study
Background Subsite and tumor stage-related heterogeneity in studies on optical tracer-guided sentinel lymph node biopsy (SLNB) in oral squamous cell carcinoma (SCC) has led to inconsistent results, limiting the applicability and wider adoption of this technique. Methodology This single-center, prospective validation study conducted in January and February 2022, included 29 consecutive patients with early-stage, node-negative SCC of the buccal mucosa undergoing methylene blue-guided SLNB followed by modified radical neck dissection (considered the reference standard) to determine the identification rate and test validity of SLNB, and secondarily, the clinicopathological factors associated with node-positivity using binary logistic regression. Results SLN identification rate with methylene blue was 93.1% with 66 SLNs retrieved in 27 patients, at a median 2 (IQR 2–3) nodes per procedure. Additionally, 644 nodes were grossed in the neck dissection specimens of 29 patients (median yield 24; IQR 17.5–26 per procedure). Overall accuracy of SLNB was 96.3% (95%CI 81.03–99.91%), with sensitivity and negative predictive value of 83.3% (95%CI 35.88–99.58%) and 95.5% (95%CI 77.16–99.88%), respectively. The only factor independently predictive of occult nodal involvement was pathological depth of infiltration (hazard ratio 3.312; 95%CI 1.040–10.546, p = 0.043) which at 6.5 mm was 100% sensitive and 91.3% specific (area under curve 0.975; 95%CI 0.925–1.000). Conclusion Methylene blue-guided SLNB may be considered a viable alternative to evaluate the neck in early-stage buccal mucosal SCC with acceptable test validity and reliability. [Registered with the Clinical Trials Registry of India (CTRI/2022/01/039523 dated 18th January 2022)].
- 28 May 2024
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 15 (4) , 661-670
Single-Tracer Methylene Blue-Guided Sentinel Lymph Node Biopsy in Early-Stage Squamous Cell Carcinoma of the Buccal Mucosa: A Prospective Study
Background Subsite and tumor stage-related heterogeneity in studies on optical tracer-guided sentinel lymph node biopsy (SLNB) in oral squamous cell carcinoma (SCC) has led to inconsistent results, limiting the applicability and wider adoption of this technique. Methodology This single-center, prospective validation study conducted in January and February 2022, included 29 consecutive patients with early-stage, node-negative SCC of the buccal mucosa undergoing methylene blue-guided SLNB followed by modified radical neck dissection (considered the reference standard) to determine the identification rate and test validity of SLNB, and secondarily, the clinicopathological factors associated with node-positivity using binary logistic regression. Results SLN identification rate with methylene blue was 93.1% with 66 SLNs retrieved in 27 patients, at a median 2 (IQR 2–3) nodes per procedure. Additionally, 644 nodes were grossed in the neck dissection specimens of 29 patients (median yield 24; IQR 17.5–26 per procedure). Overall accuracy of SLNB was 96.3% (95%CI 81.03–99.91%), with sensitivity and negative predictive value of 83.3% (95%CI 35.88–99.58%) and 95.5% (95%CI 77.16–99.88%), respectively. The only factor independently predictive of occult nodal involvement was pathological depth of infiltration (hazard ratio 3.312; 95%CI 1.040–10.546, p = 0.043) which at 6.5 mm was 100% sensitive and 91.3% specific (area under curve 0.975; 95%CI 0.925–1.000). Conclusion Methylene blue-guided SLNB may be considered a viable alternative to evaluate the neck in early-stage buccal mucosal SCC with acceptable test validity and reliability. [Registered with the Clinical Trials Registry of India (CTRI/2022/01/039523 dated 18th January 2022)].
- 25 July 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (13) , 8673-8674
ASO Visual Abstract: Prognostic Factors and Clinical Outcomes in Extraskeletal Ewing Sarcoma—A Cohort Study
- 25 July 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (13) , 8673-8674
ASO Visual Abstract: Prognostic Factors and Clinical Outcomes in Extraskeletal Ewing Sarcoma—A Cohort Study
- 2 March 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (7) , 1307-1313
Factors predicting successful resolution and long-term outcomes of benign anastomotic strictures following rectal cancer surgery
- 2 March 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (7) , 1307-1313
Factors predicting successful resolution and long-term outcomes of benign anastomotic strictures following rectal cancer surgery
- 21 February 2023
- Published by Wiley in Colorectal Disease
- Vol. 25 (6) , 1303
Pre‐sacral fascia excision for locally advanced rectal cancer: a video vignette of extended total mesorectal excision
- 21 February 2023
- Published by Wiley in Colorectal Disease
- Vol. 25 (6) , 1303
Pre‐sacral fascia excision for locally advanced rectal cancer: a video vignette of extended total mesorectal excision
- 25 January 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (5) , 3095-3096
ASO Author Reflections: Extraskeletal Ewing Sarcoma—Outcomes and Prognosticators of a Rare Malignancy
- 25 January 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (5) , 3095-3096
ASO Author Reflections: Extraskeletal Ewing Sarcoma—Outcomes and Prognosticators of a Rare Malignancy
- 23 December 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (5) , 3084-3094
Prognostic Factors and Clinical Outcomes in Extraskeletal Ewing Sarcoma: A Cohort Study
Extraskeletal Ewing sarcoma (ESE) is a lesser-known, rarer counterpart of Ewing sarcoma of bone. This single-center study sought to evaluate the prognostic
- 23 December 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (5) , 3084-3094
Prognostic Factors and Clinical Outcomes in Extraskeletal Ewing Sarcoma: A Cohort Study
Extraskeletal Ewing sarcoma (ESE) is a lesser-known, rarer counterpart of Ewing sarcoma of bone. This single-center study sought to evaluate the prognostic